BioPorto A/S

Progress in clinical trials for the FDA application for The NGAL Test™ and launch of new generic strip test

Annoucement from major shareholder

Interim financial report for Q1 2015 – the BioPorto Group

Passing of BioPorto A/S’ Annual General Meeting

Enrollment for the clinical trial of The NGAL Test™ in the US has been completed

Announcement from major shareholder regarding the AGM on April 10, 2015